DOCSLIB.ORG

Small Vessel Vasculitis Revista Colombiana De Reumatología Vol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Small Vessel Vasculitis Revista Colombiana De Reumatología Vol VOL. 14 No. 3 - 2007 SMALL VESSEL VASCULITIS REVISTA COLOMBIANA DE REUMATOLOGÍA VOL. 14 No. 3, Septiembre 2007, pp. 187-205 © 2007, Asociación Colombiana de Reumatología ARTÍCULO DE REVISIÓN Small vessel vasculitis History, classification, etiology, histopathology, clinic, diagnosis and treatment Antonio Iglesias Gamarra1, Eric L. Matteson2, José Félix Restrepo3 Summary Resumen Small-vessel vasculitis is a convenient descriptor El término vasculitis de pequeños vasos descri- for a wide range of diseases characterized by vascular be a un grupo de enfermedades caracterizadas por inflammation of the venules, capillaries, and/or inflamación de vénulas, capilares y/o arteriolas con arterioles with pleomorphic clinical manifestations. manifestaciones clínicas pleomórficas. El fenotipo clí- The classical clinical phenotype is leukocytoclastic vas- nico clásico es la vasculitis leucocitoclástica con púr- culitis with palpable purpura, but manifestations vary pura palpable, pero con manifestaciones que varían widely depending upon the organs involved. His- ampliamente dependiendo del órgano comprometido. topathologic examination in leukocytoclastic vasculi- La histología en la vasculitis leucocitoclástica revela tis reveals angiocentric segmental inflammation, una inflamación segmentaria angiocéntrica, necrosis fibrinoid necrosis, and a neutrophilic infiltrate around fibrinoide e infiltrado neutrofílico alrededor de los the blood vessel walls with erythrocyte extravasation. vasos sanguíneos, con extravasación de eritrocitos. The etiology of small-vessel vasculitis is unknown in La etiología de las vasculitis de pequeños vasos es many cases, but in others, drugs, post viral syndromes, desconocida, en muchos casos, pero en otros se ha malignancy, primary vasculitis such as microscopic pol- asociado con drogas, síndromes post virales, neo- yarteritis, and connective tissue disorders are associ- plasias, vasculitis primarias como la poliarteritis mi- ated. The diagnosis of small-vessel vasculitis relies croscópica, y enfermedades del tejido conjuntivo. El on a thorough history and physical examination, as well diagnóstico de las vasculitis de pequeños vasos se as relevant antibody testing including antinuclear an- basa en la historia clínica y el examen físico, así como tibody and antineutrophil cytoplasmic antibody, hepa- con estudio de anticuerpos como los anticuerpos titis B and C serologies, assessment of complement, antinucleares y los anticuerpos contra el citoplasma immunoglobulins, blood count, serum creatinine, liver de los neutrófilos, serología de hepatitis B y C, de- function tests, urinalysis, radiographic imaging, and terminación de inmunoglobulinas, complemento, biopsy. The treatment is based primarily on corticos- creatinina sérica, función renal, urianálisis, estudios teroid and immunosuppressive agents. de imágenes y biopsia. El tratamiento se basa prima- riamente en el uso de corticosteroides e inmuno- Key words: vasculitis, small vessel vasculitis, supresores. leukocytoclastic vasculitis, linphomonocitic vascu- litis, ANCA associated vasculitis. Palabras clave: vasculitis, vasculitis de peque- ños vasos, vasculitis leucocitoclástica, vasculitis linfomonocítica, vasculitis asociada a ANCA. 1 Profesor Titular de Medicina Interna y Reumatología. Universidad Na- cional de Colombia. 2 Division of Rheumatology, Mayo Clinic College of Medicine. 3 Profesor Titular de Medicina Interna y Reumatología. Universidad Na- Recibido: junio 29/2007 cional de Colombia. Aceptado: agosto 30/2007 187 IGLESIAS GAMARRA A. & Cols. Rev.Colomb.Reumatol. Introduction taining the sample. These variables affect and aid verification of the diagnosis. A positive biopsy sup- The systemic inflammatory vascular diseases are ports the diagnosis, while a negative one does not a heterogeneous group of conditions whose com- necessarily exclude it. This may be the case, for ex- mon feature is that of vessel inflammation. This vas- ample, when vasculitis affects an organ or append- culitis is characterized by fibrinoid necrosis, age which is poorly amenable to biopsy or biopsy thrombosis, and sometimes a granulomatous reac- of apparently involved tissue demonstrates a non- tion1. Vascular damage may occur in venules, capil- inflammatory vasculopathy1,2. laries, and arterioles, causing local and systemic Small vessel vasculitis with cutaneous involve- clinical manifestations, depending on the organs in- ment does not constitute a subgroup of either pri- volved. Vessels of any type in any organ can be af- mary or secondary vasculitis. Rather, it can be fected, a fact that result in a wide variety of sign and associated with a number of comorbidities, further symptoms. The clinical picture of small vessel vas- complicating diagnosis and, hence, treatment deci- culitis is also dependent on the extent of vascular sions. As an example, patients with small vessel dis- bed involvement, delay in diagnosis, and treatment1. ease may have hepatitis B or C, with or without These heterogeneous clinical manifestations, com- cryoglobulinemia. bined with the etiologic non specificity of the histo- logic lesions, complicate the diagnosis of specific The discovery that autoantibodies against cyto- form of vasculitis. plasmic antigens of neutrophils (anti-neutrophil cytoplasmic antibodies (ANCA)) are closely asso- Recognition of these features of vasculitis and ciated with vasculitic disorders has improved diag- evaluation with selected laboratory and other clini- nosis of patients with clinically suspected vasculitis cal tests and histologic evaluation of biopsy speci- and/or glomerulonephritis (GN). Like the introduc- mens generally permits a specific diagnosis, which tion of ANA serology for systemic lupus erytema- directs the evaluation of activity, extent, and dam- tosus, introduction of ANCA testing for vasculitis age, and guides treatment. However, signs and has revealed myriad clinicopathological presenta- symptoms of various forms of vasculitis are over- tions beyond the previously recognized patterns of lapping, and diagnostic precision is often hampered systemic disease3. As a clinicopathological proc- by the lack of diagnosis-specific histologic findings. ess, vasculitis occurs both as a primary process or This creates a clinical dilemma, because the treat- idiopathic vasculitis and as a secondary feature of ment and prognosis of specific forms of vasculitis other diseases secondary vasculitis such as colla- varies. For example, a patient with cutaneous leuko- gen vascular diseases, infectious disorders, malig- cytoclastic vasculitis with abdominal and renal nancy and adverse drugs reaction. involvement may have disease due to classic pol- The vasculitic syndromes share a common his- yarteritis nodosa (PAN) or to microscopic polyan- topathological substrate inflammation within blood giitis, or Henoch-Schönlein purpura. Indeed, there vessels resulting in vascular obstruction with tissue are few clinical conditions which cause as much ischemia and infarction. Focal necrotizing lesions are confusion and consternation among clinicians and the common vascular pathology that characterizes patients alike as do the protean presentations and the ANCA-associated disorders: Wegener’s granu- 1,2 management of vasculitis . lomatosis (WG), microscopic polyangiitis (MPA) and The gold standard for a diagnosis of vasculitis is Churg-Strauss syndrome (CSS). These lesions can histologic confirmation on biopsy, as few forms of affect many types of vessel and lead to a variety of vasculitis have a pathognomonic laboratory or symptoms and signs. Immunohistology shows little imaging finding. Interpretation of the biopsy sam- deposition of immune reactants, a feature which dis- ple is dependent on a number of variables, includ- tinguishes lesions due to ANCA-associated vasculi- ing the interest and experience of the pathologist, tis (AAV) from those of antiglomerular basement tissue selection and quantity, and the amount of time membrane disease, IgA nephropathy, and lupus which has occurred between diseases onset and ob- nephritis3. 188 VOL. 14 No. 3 - 2007 SMALL VESSEL VASCULITIS ANCA were first described in 1982 by Davies introduced in 1808 was expanded on by Bauer in and his associates as a cause of diffuse granular cy- 182421, 22. A unifying concept of purpura and its rela- toplasmic inmuno-fluorescence staining (C-ANCA) tionship to leukocytoclastic vasculitis was put forward on ethanol-fixed neutrophils in association with by Zeek et al. in 1948 and 1952, who called this form glomerulonephritis, vasculitis and Wegener’s granu- of vasculitis with small vessel involvement hypersen- lomatosis4. Two years later, Hall et al. confirmed this sitivity angitis23, 24. Davson et al. and Godman et al. observation in four patients with small-vessel vas- referred to it as microscopic polyangiitis, a concept culitis5. Van der Woude et al.6 in 1985 generated sub- adopted by the Chapel Hill international consensus con- stantial interest by suggesting that detection of ANCA ference in 1994, at which time several forms of small was a useful diagnostic and prognostic marker for vessel vasculitis were more clearly defined15, 25, 26. Wegener´s granulomatosis. Subsequent work by Van This progress was the direct result of William’s early der Woude et al. Falk et al. and others demonstrated work. He clearly distinguished purpura caused by that ANCA are closely associated with three major systemic febrile infections from non infectious pur- categories of small-vessel vasculitis: Wegener´s pura20, 21, 27.
Load more

Recommended publications
  • Apixaban-Induced Cutaneous Hypersensitivity: a Case Series with Evidence of Cross-Reactivity
    Volume 26 Number 10| October 2020| Dermatology Online Journal || Letter 26(10):20 Apixaban-induced cutaneous hypersensitivity: a case series with evidence of cross-reactivity Nasro A Isaq1 BS, Whitney M Vinson2 MD, Sahand Rahnama-Moghadam2 MD MS Affiliations: 1Indiana University School of Medicine, Indianapolis, Indiana, USA, 2Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, USA Corresponding Author: Sahand Rahnama-Moghadan MD MS, Department of Dermatology, Indiana University School of Medicine, 545 Barnhill Drive, Emerson Hall 139, Indianapolis, IN 46202, Tel: 317-944-7744, Email: [email protected] Keywords: novel oral anticoagulants (NOACs), apixaban, 2 weeks she developed low-grade fevers, chills, rivaroxaban, drug induced rash, apixaban hypersensitivity nausea, shortness of breath, headaches, and cough. reaction, rivaroxaban cross reactivity, novel oral She was admitted to the hospital where computed anticoagulant induced hypersensitivity reaction, apixaban tomography of the chest demonstrated ground glass induced rash opacities located peripherally within her lungs. Laboratory results showed a decrease in hemoglobin, elevated dsDNA, positive rheumatoid To the Editor: factor, and elevated beta-2 glycoprotein concerning Atrial fibrillation is the most common cardiac arrhythmia affecting more than 2.7 million patients for drug-induced lupus. Her apixaban was held owing to concern for hemorrhage. A in the US [1]. As the population ages, it is predicted bronchoalveolar lavage was performed revealing to affect more than 6-12 million people by 2050 [1]. eosinophilic predominance, suggestive of Patients with atrial fibrillation are at increased risk for eosinophilic pneumonia secondary to a connective thromboembolic events and require anticoagulation therapy to prevent thrombus formation and stroke. tissue disease versus drug reaction.
    [Show full text]
  • Visual Recognition of Autoimmune Connective Tissue Diseases
    Seeing the Signs: Visual Recognition of Autoimmune Connective Tissue Diseases Utah Association of Family Practitioners CME Meeting at Snowbird, UT 1:00-1:30 pm, Saturday, February 13, 2016 Snowbird/Alta Rick Sontheimer, M.D. Professor of Dermatology Univ. of Utah School of Medicine Potential Conflicts of Interest 2016 • Consultant • Paid speaker – Centocor (Remicade- – Winthrop (Sanofi) infliximab) • Plaquenil – Genentech (Raptiva- (hydroxychloroquine) efalizumab) – Amgen (etanercept-Enbrel) – Alexion (eculizumab) – Connetics/Stiefel – MediQuest • Royalties Therapeutics – Lippincott, – P&G (ChelaDerm) Williams – Celgene* & Wilkins* – Sanofi/Biogen* – Clearview Health* Partners • 3Gen – Research partner *Active within past 5 years Learning Objectives • Compare and contrast the presenting and Hallmark cutaneous manifestations of lupus erythematosus and dermatomyositis • Compare and contrast the presenting and Hallmark cutaneous manifestations of morphea and systemic sclerosis Distinguishing the Cutaneous Manifestations of LE and DM Skin involvement is 2nd most prevalent clinical manifestation of SLE and 2nd most common presenting clinical manifestation Comprehensive List of Skin Lesions Associated with LE LE-SPECIFIC LE-NONSPECIFIC Cutaneous vascular disease Acute Cutaneous LE Vasculitis Leukocytoclastic Localized ACLE Palpable purpura Urticarial vasculitis Generalized ACLE Periarteritis nodosa-like Ten-like ACLE Vasculopathy Dego's disease-like Subacute Cutaneous LE Atrophy blanche-like Periungual telangiectasia Annular Livedo reticularis
    [Show full text]
  • Review Cutaneous Patterns Are Often the Only Clue to a a R T I C L E Complex Underlying Vascular Pathology
    pp11 - 46 ABstract Review Cutaneous patterns are often the only clue to a A R T I C L E complex underlying vascular pathology. Reticulate pattern is probably one of the most important DERMATOLOGICAL dermatological signs of venous or arterial pathology involving the cutaneous microvasculature and its MANIFESTATIONS OF VENOUS presence may be the only sign of an important underlying pathology. Vascular malformations such DISEASE. PART II: Reticulate as cutis marmorata congenita telangiectasia, benign forms of livedo reticularis, and sinister conditions eruptions such as Sneddon’s syndrome can all present with a reticulate eruption. The literature dealing with this KUROSH PARSI MBBS, MSc (Med), FACP, FACD subject is confusing and full of inaccuracies. Terms Departments of Dermatology, St. Vincent’s Hospital & such as livedo reticularis, livedo racemosa, cutis Sydney Children’s Hospital, Sydney, Australia marmorata and retiform purpura have all been used to describe the same or entirely different conditions. To our knowledge, there are no published systematic reviews of reticulate eruptions in the medical Introduction literature. he reticulate pattern is probably one of the most This article is the second in a series of papers important dermatological signs that signifies the describing the dermatological manifestations of involvement of the underlying vascular networks venous disease. Given the wide scope of phlebology T and its overlap with many other specialties, this review and the cutaneous vasculature. It is seen in benign forms was divided into multiple instalments. We dedicated of livedo reticularis and in more sinister conditions such this instalment to demystifying the reticulate as Sneddon’s syndrome. There is considerable confusion pattern.
    [Show full text]
  • ANCA--Associated Small-Vessel Vasculitis
    ANCA–Associated Small-Vessel Vasculitis ISHAK A. MANSI, M.D., PH.D., ADRIANA OPRAN, M.D., and FRED ROSNER, M.D. Mount Sinai Services at Queens Hospital Center, Jamaica, New York and the Mount Sinai School of Medicine, New York, New York Antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis is the most common primary sys- temic small-vessel vasculitis to occur in adults. Although the etiology is not always known, the inci- dence of vasculitis is increasing, and the diagnosis and management of patients may be challenging because of its relative infrequency, changing nomenclature, and variability of clinical expression. Advances in clinical management have been achieved during the past few years, and many ongoing studies are pending. Vasculitis may affect the large, medium, or small blood vessels. Small-vessel vas- culitis may be further classified as ANCA-associated or non-ANCA–associated vasculitis. ANCA–asso- ciated small-vessel vasculitis includes microscopic polyangiitis, Wegener’s granulomatosis, Churg- Strauss syndrome, and drug-induced vasculitis. Better definition criteria and advancement in the technologies make these diagnoses increasingly common. Features that may aid in defining the spe- cific type of vasculitic disorder include the type of organ involvement, presence and type of ANCA (myeloperoxidase–ANCA or proteinase 3–ANCA), presence of serum cryoglobulins, and the presence of evidence for granulomatous inflammation. Family physicians should be familiar with this group of vasculitic disorders to reach a prompt diagnosis and initiate treatment to prevent end-organ dam- age. Treatment usually includes corticosteroid and immunosuppressive therapy. (Am Fam Physician 2002;65:1615-20. Copyright© 2002 American Academy of Family Physicians.) asculitis is a process caused These antibodies can be detected with indi- by inflammation of blood rect immunofluorescence microscopy.
    [Show full text]
  • Immune-Pathophysiology and -Therapy of Childhood Purpura
    Egypt J Pediatr Allergy Immunol 2009;7(1):3-13. Review article Immune-pathophysiology and -therapy of childhood purpura Safinaz A Elhabashy Professor of Pediatrics, Ain Shams University, Cairo Childhood purpura - Overview vasculitic disorders present with palpable Purpura (from the Latin, purpura, meaning purpura2. Purpura may be secondary to "purple") is the appearance of red or purple thrombocytopenia, platelet dysfunction, discolorations on the skin that do not blanch on coagulation factor deficiency or vascular defect as applying pressure. They are caused by bleeding shown in table 1. underneath the skin. Purpura measure 0.3-1cm, A thorough history (Table 2) and a careful while petechiae measure less than 3mm and physical examination (Table 3) are critical first ecchymoses greater than 1cm1. The integrity of steps in the evaluation of children with purpura3. the vascular system depends on three interacting When the history and physical examination elements: platelets, plasma coagulation factors suggest the presence of a bleeding disorder, and blood vessels. All three elements are required laboratory screening studies may include a for proper hemostasis, but the pattern of bleeding complete blood count, peripheral blood smear, depends to some extent on the specific defect. In prothrombin time (PT) and activated partial general, platelet disorders manifest petechiae, thromboplastin time (aPTT). With few exceptions, mucosal bleeding (wet purpura) or, rarely, central these studies should identify most hemostatic nervous system bleeding;
    [Show full text]
  • Vasculitis: Pearls for Early Diagnosis and Treatment of Giant Cell Arteritis
    Vasculitis: Pearls for early diagnosis and treatment of Giant Cell Arteritis Mary Beth Humphrey, MD, PhD Professor of Medicine McEldowney Chair of Immunology [email protected] Office Phone: 405 271-8001 ext 35290 October 2019 Relevant Disclosure and Resolution Under Accreditation Council for Continuing Medical Education guidelines disclosure must be made regarding relevant financial relationships with commercial interests within the last 12 months. Mary Beth Humphrey I have no relevant financial relationships or affiliations with commercial interests to disclose. Experimental or Off-Label Drug/Therapy/Device Disclosure I will be discussing experimental or off-label drugs, therapies and/or devices that have not been approved by the FDA. Objectives • To recognize early signs of vasculitis. • To discuss Tocilizumab (IL-6 inhibitor) as a new treatment option for temporal arteritis. • To recognize complications of vasculitis and therapies. Professional Practice Gap Gap 1: Application of imaging recommendations in large vessel vasculitis Gap 2: Application of tocilizimab in treatment of giant cell vasculitis Cranial Symptoms Aortic Vision loss Aneurysm GCA Arm PMR Claudication FUO Which is not a risk factor or temporal arteritis? A. Smoking B. Female sex C. Diabetes D. Northern European ancestry E. Age Which is not a risk factor or temporal arteritis? A. Smoking B. Female sex C. Diabetes D. Northern European ancestry E. Age Giant Cell Arteritis • Most common form of systemic vasculitis in adults – Incidence: ~ 1/5,000 persons > 50 yrs/year – Lifetime risk: 1.0% (F) 0.5% (M) • Cause: unknown At risk: Women (80%) > men (20%) Northern European ancestry>>>AA>Hispanics Age: average age at onset ~73 years Smoking: 6x increased risk Kermani TA, et al Ann Rheum Dis.
    [Show full text]
  • DIFFERENTIAL DIAGNOSIS of Hypersensitivity Vasculitis
    HIGHLIGHTS FROM MEDICAL GRAND ROUNDS renal disease also is rare. However, certain types of kidney posure to an exogenous antigen such as a drug, serum, disease are associated with a higher incidence of hyper- toxin, or to an infection. Typically, the onset of vasculitis uricemia and gout, including chronic lead nephropathy, occurs 7 to 10 days after exposure to the antigen. The polycystic disease, amyloidosis, analgesic nephropathy, characteristic rash presents as palpable purpura, although and medullary cystic disease. Hypertension and its ulcers, nodules, bullae, or urticaria also may develop in therapy are associated with an increased incidence of some patients. hyperuricemia and gout. On biopsy, the lesions display polymorphonuclear The management of concurrent marked hyper- leukocytes and associated leukocytoclasis, but the in- uricemia and chronic renal disease is directed to preser- filtrates may be predominantly mononuclear. Im- vation of renal function, blood pressure control, and munofluorescent studies often show deposition of com- reduction of the serum uric acid. Uric acid homeostasis plement and immunoglobulins in vessel walls, and other can be achieved by maintaining urine flow (>2 L/d), techniques may show soluble immune complexes and restricting dietary purines and excessive alcohol, and, if evidence of complement activation; however, these needed, allopurinol in the lowest dose that can main- laboratory findings are neither universal nor necessary for tain a near-normal serum uric acid. Therapy should the diagnosis. start with 50 mg/d and increase in 50-mg increments The clinical course is usually self-limited. Varying until the level is under control. Generally, the dosage is degrees of fever, malaise, and weight loss may occur and 100 mg/d for every 30 cc/min of GFR.
    [Show full text]
  • Teledermatology and Common Dermatology Issues in the Hospitalized Patient
    Teledermatology and Common Dermatology Issues in the Hospitalized Patient Patricia Meyer, DNP, CRNP, FNP‐BC, AGACNP‐BC, NE‐BC The Rise of Teledermatology Improve Shortage of Ability for dermatology dermatology dermatologist to access providers see more patients • Obtaining a CC, HPI, ROS, Allergies, Med list , PMH, Social and Family Hx • A problem‐focused exam • Digital imaging • Uploading of‐ CC, HPI, ROS, Allergies, Med list , PMH, Social and Family Hx, Physical exam, and digital images via secure computer site • Onsite person to obtain BX if needed Teledermatology What is Involved After Info is Uploaded • Dermatologist will form differential diagnosis • Suggest a work up • Formulate and assessment and plan Teledermatology What is Involved • Medication list, prescription and over‐the‐counter drugs • History of past reactions to drugs or foods, topicals, soaps, detergents • Any recent illness ? Exposure to others with similar s/s • Any concurrent infections, metabolic disorders, or immunocompromise, or hx of History Needed autoimmune issues, hx of CA? • Any note in correlation with medication administration and rash onset? • How was medication administered? • Improvement if medication stopped and symptom reoccurrence if medication restarted? Worrisome • Mucous membrane erosions • Blisters Physical Exam • Nikolsky sign Features and • Confluent erythema symptoms • Angioedema and tongue swelling • Palpable purpura • Skin necrosis • Lymphadenopathy • High fever, dyspnea, or hypotension HJ is a 82 year old male, who was admitted from SNF, due to abd pain. HJ is being treated for diverticulitis with Cipro and Flagyl. Teledermatolgy is consulted due to a “rash.” Per the patient’s RN , “it is unclear if this is a new drug rash”. Upon further review with patient he states that he has had this rash for some time “it is very itchy and often keeps me up at night .” He denies any worsening or improving factors.
    [Show full text]
  • Audio Vestibular Gluco Corticoid General and Local Or Cytotoxic Agents
    Global Journal of Otolaryngology ISSN 2474-7556 Case Report Glob J Otolaryngol Volume 13 Issue 5 - March 2018 Copyright © All rights are reserved by Cristina Otilia Laza DOI: 10.19080/GJO.2018.13.555871 Autoimmune Granulomatosis with Polyangiitis or Wegener Granulomatosis Cristina Otilia Laza1*, Gina Enciu2, Luminita Micu2 and Maria Suta3 1Department of ENT, County Clinical Emergency Hospital of Constanta, Romania 2Department of Anatomo pathology, County Clinical Emergency Hospital of Constanta, Romania 3Department of Rheumatology, County Clinical Emergency Hospital of Constanta, Romania Submission: February 19, 2018; Published: March 14, 2018 *Corresponding author: Cristina Otilia Laza, Department of ENT, County Clinical Emergency Hospital of Constanta, Romania, Email: Abstract Granulomatosis with polyangiitis, formerly known as Wegener granulomatosis, is a disease that typically consists of a triad of airway necrotizing granulomas, systemic vasculitis, and focal glomerulonephritis. If the disease does not involve the kidneys, it is called limited granulomatosis with polyangiitis. The etiology and pathogenesis of WG are unknown. Infectious, genetic, and environmental risk factors and combinations thereof have been proposed. The evidence to date suggests that WG is a complex, immune-mediated disorder in which tissue production of ANCA, directed against antigens present within the primary granules of neutrophils and monocytes; these antibodies produce tissueinjury damageresults from by interacting the interplay with of primedan initiating neutrophils inflammatory and endothelial event and cells a highly The purposespecific immune of this article response. is to Part present of this 4 patients response all consists diagnosed of the in our department ,with head and neck lesions ,every case with his manifestation and response to the treatment .We consider that a well trained ENT specialist must be able to diagnose and recognize such a disease but this requires knowledge and hard work.
    [Show full text]
  • Orphanet Encyclopædia 2003. Giant Cell Arteritis
    Giant cell arteritis Author: Doctor José María Calvo-Romero1 Creation Date: June 2003 Scientific Editor: Professor Loic Guillevin 1Department of Internal Medicine, Hospital de Zafra, Antigua Ctra. Nacional 432, 06300 Zafra (Badajoz), Spain. [email protected] Abstract Key-words Disease names Definition Epidemiology Etiology Clinical manifestations Laboratory findings Diagnosis Treatment Prognosis References Abstract Giant cell arteritis (GCA) or temporal arteritis is a systemic vasculitis which involves large and medium- sized vessels, especially the extracranial branches of the carotid artery, usually in persons older than 50 years. Feared complications of GCA are permanent visual loss, ischaemic strokes and thoracic and abdominal aortic aneurysms. The treatment consists of high-dose steroids. Mortality in patients with GCA seems to be similar to that of controls, probably due to a correct diagnosis and management. GCA is the most common systemic vasculitis in Western countries. The incidence rates described in European countries are around 20:100 000 persons older than 50 years. Key-words vasculitis, giant cell arteritis, temporal arteritis, Horton’s arteritis, large and medium-sized vessels disorder. Disease names Table 1: The Chapel Hill Consensus Giant cell arteritis Conference on the Nomenclature of Systemic Temporal arteritis Vasculitis Horton’s arteritis Large Vessel Vasculitis Giant cell arteritis Definition Takayasu arteritis Giant cell arteritis (GCA) is a relatively common Medium Vessel Vasculitis systemic vasculitis in Europe. GCA involves Polyarteritis nodosa large and medium-sized vessels in patients Kawasaki’s disease usually older than 50 years. It is a Small Vessel Vasculitis granulomatous arteritis of the aorta and its major Wegener’s granulomatosis branches, especially the extracranial branches of Churg-Strauss syndrome Microscopic polyangiitis the carotid artery.
    [Show full text]
  • Understanding the Cryoglobulinemias
    Current Rheumatology Reports (2019) 21:60 https://doi.org/10.1007/s11926-019-0859-0 VASCULITIS (L ESPINOZA, SECTION EDITOR) Understanding the Cryoglobulinemias Alejandro Fuentes1 & Claudia Mardones1 & Paula I. Burgos1 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of the Review Cryoglobulins are immunoglobulins with the ability to precipitate at temperatures <37 °C. They are related to hematological disorders, infections [especially hepatitis C virus (HCV)], and autoimmune diseases. In this article, the state of the art on Cryoglobulinemic Vasculitis (CV), in a helpful and schematic way, with a special focus on HCV related Mixed Cryoglobulinemia treatment are reviewed. Recent Findings Direct – acting antivirals (DAA) against HCV have emerged as an important key in HCV treatment to related Cryoglobulinemic Vasculitis, and should be kept in mind as the initial treatment in non–severe manifestations. On the other hand, a recent consensus panel has published their recommendations for treatment in severe and life threatening manifestations of Mixed Cryoglobulinemias. Summary HCV-Cryoglobulinemic vasculitis is the most frequent form of CV. There are new treatment options in HCV-CV with DAA, with an important number of patients achieving complete response and sustained virologic response (SVR). In cases of severe forms of CV, treatment with Rituximab and PLEX are options. The lack of data on maintenance therapy could impulse future studies in this setting. Keywords HCV . Mixed Cryoglobulinemia . Type I Cryoglobulinemia . gC1qR . Direct-acting antivirals . Rituximab Introduction and Definitions tion of the total pool of cryoprecipitable immunocomplexes in targeted vessels and due to false negative results owing to im- Cryoglobulins are immunoglobulins (Ig) that precipitate in vitro proper blood sampling or inadequate laboratory processes [4].
    [Show full text]
  • Microscopic Polyangiitis
    Supplementary material Ann Rheum Dis Supplementary Methods Polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA, Wegener’s), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) were defined according to the Chapel Hill definitions. In ANCA-associated vasculitis patients, serum samples were tested for ANCA by means of indirect immunofluorescence and tested for anti–proteinase 3 ANCA and anti-myeloperoxidase ANCA with an enzyme-linked immunosorbent assay. Virus-associated vasculitides were excluded from all these trials and patients with a previous history of cancer of less than 3 or 5 years were ineligible for all trials. Patients were prospectively evaluated at diagnosis, at randomization, every 2-3 months thereafter during the first two years of follow-up, and then every 6 months until the end of follow-up. Long-term follow-up after the end of the protocol was planned for each protocol using the FVSG database. Severe adverse events, including malignancy, were prospectively collected. Lifestyle factors such as smoking were not included in this analysis Association of baseline characteristics and therapeutic strategies with the occurence of malignancy was investigated by univariate analyses using Cox regression models. Variables associated with malignancies with a P value <0.05 in univariate analysis were included in a backward-selection Cox regression analysis. Person-years of follow-up were calculated using the total follow-up and stratified by sex and 5-years age groups. Incidence rates were calculated for all cancers and compared to the French National registry, with indirect standardization on sex and 5-years age groups. Standardized incidence ratios were calculated as the ratio between the observed and the expected number of cancer.
    [Show full text]